CL2018001590A1 - Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina. - Google Patents

Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.

Info

Publication number
CL2018001590A1
CL2018001590A1 CL2018001590A CL2018001590A CL2018001590A1 CL 2018001590 A1 CL2018001590 A1 CL 2018001590A1 CL 2018001590 A CL2018001590 A CL 2018001590A CL 2018001590 A CL2018001590 A CL 2018001590A CL 2018001590 A1 CL2018001590 A1 CL 2018001590A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
phenylaminopyrimidine derivative
solid dispersion
formulation
benzamida
Prior art date
Application number
CL2018001590A
Other languages
English (en)
Inventor
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Durga Maheswari Parvataneni
Mitrabhanu Mohanty
Venkata Satyanarayana Appadwedula
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of CL2018001590A1 publication Critical patent/CL2018001590A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULACION ORAL EN FORMA DE DISPERSION SOLIDA QUE COMPRENDE (3,5-BIS-TRIFLUOROMETIL)-N-[4-METIL-3-(4-PIRIDIN-3-IL-PIRIMIDIN-2-IL-AMINO)FENIL]BENZAMIDA (NRC-AN-019) O UNA DE SUS SALES Y AL MENOS UN AGENTE DE MATRIZ POLIMERICA; PROCESO DE OBTENCION DE LA DISPERSION SOLIDA; Y USO DE LA FORMULACION PARA EL TRATAMIENTO DE CANCER.
CL2018001590A 2015-12-18 2018-06-14 Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina. CL2018001590A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18

Publications (1)

Publication Number Publication Date
CL2018001590A1 true CL2018001590A1 (es) 2018-11-30

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001590A CL2018001590A1 (es) 2015-12-18 2018-06-14 Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.

Country Status (32)

Country Link
US (1) US10383872B2 (es)
EP (1) EP3389633B1 (es)
JP (2) JP6896738B2 (es)
KR (1) KR20180102584A (es)
CN (1) CN108495620B (es)
AU (1) AU2016373574B2 (es)
BR (1) BR112018012458A2 (es)
CA (1) CA3008634A1 (es)
CL (1) CL2018001590A1 (es)
CO (1) CO2018007112A2 (es)
CY (1) CY1124580T1 (es)
DK (1) DK3389633T3 (es)
EA (1) EA036513B1 (es)
ES (1) ES2881883T3 (es)
GB (1) GB2564262A (es)
GE (1) GEP20207176B (es)
HK (1) HK1254573A1 (es)
HR (1) HRP20211590T1 (es)
HU (1) HUE056269T2 (es)
IL (1) IL260085B (es)
LT (1) LT3389633T (es)
MA (1) MA44079B1 (es)
MX (1) MX2018007281A (es)
PH (1) PH12018501292A1 (es)
PL (1) PL3389633T3 (es)
PT (1) PT3389633T (es)
RS (1) RS62422B1 (es)
SG (1) SG11201805142RA (es)
SI (1) SI3389633T1 (es)
UA (1) UA122592C2 (es)
WO (1) WO2017103941A1 (es)
ZA (1) ZA201804203B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
WO2019220282A1 (en) * 2018-05-14 2019-11-21 Capsugel Belgium Nv Solid dosage forms with high active agent loading
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
CA2591321C (en) 2004-09-09 2013-09-24 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
EP3082803A4 (en) * 2013-12-20 2017-05-31 Phosphorex Inc. Indirubin solid dispersion composition

Also Published As

Publication number Publication date
CA3008634A1 (en) 2017-06-22
HRP20211590T1 (hr) 2022-01-07
US10383872B2 (en) 2019-08-20
PL3389633T3 (pl) 2021-12-13
EP3389633A4 (en) 2019-08-07
RS62422B1 (sr) 2021-10-29
ZA201804203B (en) 2020-08-26
EP3389633B1 (en) 2021-07-14
SI3389633T1 (sl) 2021-11-30
ES2881883T3 (es) 2021-11-30
WO2017103941A1 (en) 2017-06-22
JP2021059551A (ja) 2021-04-15
US20190015412A1 (en) 2019-01-17
CO2018007112A2 (es) 2018-07-19
MX2018007281A (es) 2018-11-29
IL260085A (en) 2018-07-31
CN108495620B (zh) 2021-09-03
HK1254573A1 (zh) 2019-07-19
SG11201805142RA (en) 2018-07-30
IL260085B (en) 2021-09-30
BR112018012458A2 (pt) 2018-12-18
KR20180102584A (ko) 2018-09-17
PT3389633T (pt) 2021-08-05
DK3389633T3 (da) 2021-08-30
GB201811142D0 (en) 2018-08-22
PH12018501292A1 (en) 2019-02-04
JP6896738B2 (ja) 2021-06-30
AU2016373574A1 (en) 2018-07-12
CY1124580T1 (el) 2022-07-22
LT3389633T (lt) 2021-09-10
AU2016373574B2 (en) 2021-10-14
HUE056269T2 (hu) 2022-02-28
CN108495620A (zh) 2018-09-04
EA036513B1 (ru) 2020-11-18
UA122592C2 (uk) 2020-12-10
GB2564262A (en) 2019-01-09
EA201891443A1 (ru) 2019-01-31
MA44079A (fr) 2021-04-21
GEAP201614833A (es) 2020-06-25
MA44079B1 (fr) 2021-10-29
JP2018538325A (ja) 2018-12-27
EP3389633A1 (en) 2018-10-24
GEP20207176B (en) 2020-11-10

Similar Documents

Publication Publication Date Title
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
SV2016005277A (es) Nanopartã�culas terapã‰uticas que comprenden un agente terapã‰utico, y mã‰todos para su elaboraciã“n y uso
UY37098A (es) Moduladores de ror-gamma
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CO2019002245A2 (es) Combinación de agonistas de fxr
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR112282A1 (es) Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
BR112018074162A2 (pt) composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.